Screening for familial ovarian cancer: poor survival of BRCA1/2 related cancers

Evans, D. Gareth; Gaarenstroom, Katja N.; Stirling, David; Shenton, Andrew; Mæhle, Lovise; Dørum, Anne; Steel, Michael; Lalloo, Fiona; Apold, Jaran; Porteous, Mary; Vasen, Hans F. A.; Asperen, Christi J. van; Møller, Pål

doi:10.1136/jmg.2008.058248

Cited by 121 publications

(90 citation statements)

References 29 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…This is shown from our own data and a combined analysis from five centres of 63 ovarian tumours in a screening programme with 10-year survival of only 36%. 21 As such, 11 ovarian cancer deaths may have been expected out of the 15.79 cancers expected in the surgical group, with one actually dying from a cancer detected at surgery. As such, close to 13 ovarian cancers and 10 ovarian cancer deaths will most likely have already been prevented in the surgery group.…”

Section: Discussionmentioning

confidence: 99%

Risk-reducing surgery for ovarian cancer: outcomes in 300 surgeries suggest a low peritoneal primary risk

et al. 2009

View full text Add to dashboard Cite

Risk-reducing salpingo-oophorectomy is currently advocated for the reduction of both breast and ovarian cancer risk in BRCA1/2 carriers, but residual risk of peritoneal primary cancer remains a concern. A sequential series of women attending a single institution for ovarian risk management underwent either risk-reducing surgery or screening. A person-years at risk analysis was used to compare observed versus expected cancers. In total, 300 women underwent risk-reducing salpingo-oophorectomy, including 160 BRCA1/2 mutation carriers. Three occult ovarian cancers were detected at surgery. There have been 2400.4 years of follow-up and 15.79 expected cancers. No peritoneal cancers have occurred. Amongst 503 women controls with 3444.3 years of follow-up, 15.93 ovarian cancers were expected and 17 were found. There were six ovarian cancer-related deaths in the control group compared with one in the surgery group. Risk-reducing salpingo-oophorectomy in a single institution has so far avoided peritoneal cancer incidence.

show abstract

Section: Discussionmentioning

confidence: 99%

Risk-reducing surgery for ovarian cancer: outcomes in 300 surgeries suggest a low peritoneal primary risk

et al. 2009

View full text Add to dashboard Cite

show abstract

“…26,27 A recent study illustrated that an annual magnetic resonance imaging (MRI) decreases the risk of advanced-stage breast cancer in women with BRCA1/2 mutations. 28 Current breast cancer screening recommendations for the BRCA mutation carrier include monthly breast self-exam beginning at 18 years of age, semiannual clinical breast exam beginning at age 25, and annual mammography and breast MRI beginning at ages [25][26][27][28][29][30][31][32][33][34][35]. 25,29 Screening should be modified based on the earliest age of onset of breast cancer in a first-degree relative in a given family.…”

Section: Screening For Breast and Ovarian Cancermentioning

confidence: 99%

Challenging and Complex Decisions in the Management of the BRCA Mutation Carrier

Stan

Shuster

Wick

et al. 2013

Journal of Women's Health

View full text Add to dashboard Cite

Women afflicted by the hereditary breast and ovarian cancer syndrome face complex decisions regarding medical interventions aimed at reducing their risk of ovarian and breast cancer, interventions which in turn may interfere with their fertility and cause early menopause. This review addresses selected topics of importance and controversy in the management of the BRCA mutation carrier, such as psychological well-being and quality of life, breast and ovarian cancer screening, risk-reducing interventions for breast cancer and ovarian cancer, the issue of hysterectomy at the time of the risk-reducing salpingo-oophorectomy, health consequences of early surgical menopause, and safety of hormonal therapy after oophorectomy. The information presented is based on an extensive review of the literature on the selected topics and on the expertise of our multidisciplinary team.

show abstract

“…Until recently, ovarian cancer screening by annual transvaginal ultrasonography and evaluation of serum CA125 was considered effective for early stage diagnosis. However, in several (retrospective) series it has been shown ineffective [2][3][4][5][6][7]. The only effective and currently available strategy is a risk reducing salpingo-oophorectomy (RRSO).…”

Section: Introductionmentioning

confidence: 99%

Short-term surgical outcome and safety of risk reducing salpingo-oophorectomy in BRCA1/2 mutation carriers

Kenkhuis¹,

Bock²,

Elferink³

et al. 2010

Maturitas

View full text Add to dashboard Cite

Screening for familial ovarian cancer: poor survival of BRCA1/2 related cancers

Abstract: Annual surveillance, by transvaginal ultrasound scanning and serum CA125 measurement, in women at increased familial risk of ovarian cancer is ineffective in detecting tumours at a sufficiently early stage to influence substantially survival in BRCA1/2 carriers.

Cited by 121 publications

References 29 publications

Risk-reducing surgery for ovarian cancer: outcomes in 300 surgeries suggest a low peritoneal primary risk

Risk-reducing surgery for ovarian cancer: outcomes in 300 surgeries suggest a low peritoneal primary risk

Challenging and Complex Decisions in the Management of the BRCA Mutation Carrier

Short-term surgical outcome and safety of risk reducing salpingo-oophorectomy in BRCA1/2 mutation carriers

Contact Info

Product

Resources

About